Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etaftoron
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Etaftoron (also known as etaftorone or OSI-1211) is a lipid-soluble 1,4-dihydropyridine (DHP) derivative developed by the Latvian Institute of Organic Synthesis. Unlike traditional dihydropyridines, etaftoron exhibits very weak calcium channel blocking activity. Instead, it acts primarily as a mitochondrial modulator, peroxynitrite scavenger, and DNA-binding agent. In preclinical models of streptozotocin-induced diabetes mellitus, etaftoron has been shown to reduce pathological nitric oxide (NO) hyperproduction, downregulate inducible nitric oxide synthase (iNOS) and xanthine oxidoreductase (XOR) expression, and upregulate endothelial nitric oxide synthase (eNOS) expression, thereby demonstrating potential protective effects against diabetic nephropathy and oxidative stress-induced DNA damage.
- Other names
- etaftaronetaftorone
02
Targets
DNA
Beyond the preview
Go deeper on etaftoron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etaftoron.